pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: HIV

Feb 22, 2023

LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate

Feb 14, 2023

ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

Nov 30, 2022

ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV

Oct 25, 2022

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Oct 20, 2022

Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure

Sep 29, 2022

Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Sep 15, 2022

Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Jul 29, 2022

ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced

Jul 28, 2022

ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine

Jun 30, 2022

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

May 17, 2022

Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting

Mar 29, 2022

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg

Mar 24, 2022

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

Mar 24, 2022

ViiV Healthcare Announces Label Update for Its Long-Acting HIV Treatment, Cabenuva (cabotegravir, rilpivirine), to Be Initiated With or Without an Oral Lead-in Period

Feb 8, 2022

Aphios Granted US Patent For Combination HIV Latency Nanoparticles Towards an HIV Cure

Feb 7, 2022

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

Feb 1, 2022

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment

Jan 27, 2022

Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Dec 21, 2021

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

Dec 20, 2021

ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

Dec 1, 2021

Medicines360 and the Population Council Pursue Agreement to Develop Product to Prevent HIV and Unintended Pregnancy for Worldwide Distribution

Oct 28, 2021

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings

Oct 28, 2021

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Sep 28, 2021

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

Sep 28, 2021

FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

Jul 26, 2021

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

Jul 17, 2021

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Jun 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology to enable development of “ultra long-acting” medicines for HIV

Jun 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

Jun 10, 2021

AUM LifeTech, Inc. to Present Preclinical Developments on Lung Cancer, Parkinson's Disease, and HIV at BIO Digital 2021

May 4, 2021

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Mar 9, 2021

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

Feb 24, 2021

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

Feb 8, 2021

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Jan 21, 2021

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Dec 21, 2020

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Dec 11, 2020

ViiV Healthcare Announces Positive CHMP Opinion for Rukobia (fostemsavir), a First-in-Class Attachment Inhibitor for the Treatment of Adults With Multidrug-Resistant HIV With Few Treatment Options Available

Dec 1, 2020

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery

Dec 1, 2020

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with 'HIV in View'--a first-of-its-kind online HIV photography gallery

Nov 17, 2020

ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

Nov 9, 2020

ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women

Oct 16, 2020

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Oct 8, 2020

ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen

Sep 15, 2020

ViiV Healthcare Announces New Research Report, “Here as I Am,” on Socio-Economic Forces Affecting Access to HIV Care for Latinx Gay and Bisexual Men

Aug 11, 2020

AUM LifeTech awarded NIH grant to develop HIV therapy using RNA targeting technology, commits additional resources to COVID-19 research

Aug 11, 2020

FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program

Jul 28, 2020

American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure Research

Jul 13, 2020

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

Jul 2, 2020

ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir), a First-in-Class Treatment for HIV in Adults With Few Treatment Options Available

Jun 12, 2020

ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV

Jun 1, 2020

Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC™ Vaccine Platform in SARS-CoV-2 and HIV

May 18, 2020

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Apr 27, 2020

ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

Mar 20, 2020

ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV

Mar 11, 2020

Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination

Mar 9, 2020

ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership

Mar 2, 2020

ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV

Feb 24, 2020

Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection

Jan 28, 2020

Aphios Granted US Patent For Combination HIV Latency Nanotherapeutic Towards an HIV Cure

Jan 10, 2020

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Dec 21, 2019

ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

Dec 5, 2019

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Nov 21, 2019

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

Nov 21, 2019

Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology

Oct 18, 2019

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

Sep 25, 2019

HemoShear Therapeutics Appoints Brian A. Johns, PhD, Chief Scientific Officer

Jul 29, 2019

ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational Cabotegravir to Be Used in Combination With Rilpivirine as the First Monthly, Injectable Treatment for HIV

Jul 24, 2019

ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection

Jul 22, 2019

ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019

Jul 10, 2019

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

Jul 9, 2019

Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Jul 2, 2019

HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development

Jul 2, 2019

American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV Functional Cure

Jul 2, 2019

HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

May 21, 2019

HIV Cure Program Patent Granted To American Gene Technologies

Apr 29, 2019

ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV

Jan 2, 2019

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

Dec 21, 2018

Viriom to Report Results from Phase 1b Clinical Trial of Once Weekly Oral HIV Treatment

Dec 20, 2018

Viriom Initiates Phase 1 Clinical Trial of Once Monthly Injectable HIV Treatment

Oct 18, 2018

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

Jul 24, 2018

ViiV Healthcare Presents Phase III Data at AIDS 2018 from Landmark GEMINI Studies Showing Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients, with No Emergence of Resistance

Jun 5, 2018

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

May 21, 2018

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV

May 3, 2018

Atreca Announces Publication of HIV Research in Cell

Apr 16, 2018

Viriom to Present Pre-Clinical Studies with Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations at the International Conference on HIV/AIDS, STDs and STIs 2018

Mar 13, 2018

Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development

Mar 5, 2018

ViiV Healthcare Announces Positive New Dolutegravir Data for the Treatment of People Living With HIV Co-Infected With Tuberculosis

Jan 9, 2018

Lyndra Announces Publication of Feasibility Study of Oral Once-Weekly Drug Delivery System for HIV Antiretroviral Therapy in Nature Communications

Dec 1, 2017

Aphios is Developing a Platform for the Delivery of siRNA-based Therapeutics Towards an HIV Cure

Oct 12, 2017

American Gene Technologies Inc. (AGT) Demonstrates Rationale of its Genetic Approach toward developing a Functional Cure for HIV Infection

Sep 26, 2017

American Gene Technologies Inc. (AGT) CSO, David Pauza, to Present HIV Functional Cure data At The Cell and Gene Meeting on the Mesa

Sep 6, 2017

HIV Cure-Focused Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures

Jul 25, 2017

ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

Jul 25, 2017

Viriom Obtains First Market Approval of Elsulfavirine (Elpida) for Treatment of HIV-1 Infection in Russia

May 2, 2017

Lyndra Secures Funding from the National Institute of Allergy and Infectious Diseases for the Development of Ultra-Long Acting Oral HIV Therapies

Jan 6, 2017

Intarcia Therapeutics Announces Upcoming Presentation at 35th Annual J.P. Morgan Healthcare Conference

Oct 5, 2016

AUM LifeTech Develops A New Approach To Combat HIV By Using FANA RNA Silencing Technology To Inhibit HIV Replication

Sep 9, 2016

Kymouse™, Kymab's Human Antibody Discovery Platform, Successfully Demonstrates Steps to Developing HIV Vaccine

Jun 10, 2016

ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV

Feb 24, 2016

ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

Feb 22, 2016

GSK's Global HIV Business ViiV Healthcare Completes Transactions to Acquire Bristol-Myers Squibb's R&D HIV Assets

Feb 22, 2016

Bristol-Myers Squibb Completes Previously Announced Sale of its HIV RandD Portfolio to ViiV Healthcare

Jan 19, 2016

ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

Jan 7, 2016

Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable Regimen for Treatment of HIV Infection

Dec 18, 2015

Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare

Dec 18, 2015

Bristol-Myers Squibb to Sell its HIV RandD Portfolio to ViiV Healthcare

Nov 3, 2015

ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

Oct 26, 2015

ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally

Sep 10, 2015

IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

Jun 2, 2015

Aphios Completes Enrollment in Phase I/II Clinical Trial Towards an HIV Cure

May 26, 2015

ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV

May 6, 2015

ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

Oct 20, 2014

ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.

Jul 21, 2014

Argos Therapeutics Presents Data Showing the Impact of HIV Antigen Sequence Divergence on Durable Viral Control Following Treatment With Autologous Immune Therapy

Jun 12, 2014

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

May 24, 2014

Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies Discovered with Theraclone Technology

Apr 1, 2014

Medicines Patent Pool, ViiV Healthcare Sign Licence for the Most Recent HIV Medicine to Have Received Regulatory Approval

Apr 1, 2014

ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

Jan 21, 2014

ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

Nov 4, 2013

Theraclone Sciences’ Monoclonal Antibody Candidate PGT121 Suppresses HIV in Simian Models of Disease

Sep 17, 2013

Profectus BioSciences Announces Initiation of Clinical Trial Evaluating its Therapeutic HIV Vaccine in Support of the “Cure Agenda”

Dec 4, 2012

Profectus BioSciences’ Vesicular Stomatitis Virus-Vectored HIV-1 Vaccine Safe and Immunogenic in Government Sponsored Phase 1 Trial

Jul 18, 2012

ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment

Jul 11, 2012

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Apr 2, 2012

Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV

Feb 7, 2012

Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen

Jan 4, 2012

First Human Volunteer Immunized in Clinical Trial of Profectus BioSciences’ Vesicular Stomatitis Virus-vectored HIV-1 Vaccine

Oct 11, 2011

ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV

Jun 28, 2011

Argos Therapeutics to Participate in Panel Discussion on Innovative Approaches to HIV Vaccine Development and Immunotherapies at 2011 BIO International Convention

May 25, 2011

The ACTG Immunizes First Subject in Clinical Trial of Profectus BioSciences’ Therapeutic HIV DNA Vaccine

Jan 5, 2011

Profectus BioSciences Announces Initiation of Clinical Trial of IL-12 Enhanced Therapeutic HIV DNA Vaccine Delivered Using Electroporation

Dec 9, 2010

Argos Therapeutics' Arcelis™ HIV Immunotherapy Shows Feasibility to Generate Fully Functional Dendritic Cells From Viremic Patients

Oct 21, 2010

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

Oct 12, 2010

ViiV Healthcare Acts to Improve Access to HIV Medicines in United States for Those Most in Need

Oct 5, 2010

Profectus BioSciences, Inc. Receives $4.4M in Grants to Develop an HIV Prophylactic Vaccine

Jul 21, 2010

Shionogi-ViiV Healthcare Announces Commitment to Phase III Development Program for Investigational Once-Daily HIV Integrase Inhibitor

Mar 2, 2010

Ichor Medical Systems and Profectus Biosciences Enter into an Agreement for Use of TriGrid™ Electroporation Device to Develop Multiple DNA Vaccines

Mar 30, 2009

Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc.

Dec 8, 2008

Profectus BioSciences Awarded $21.6 Million in NIH Contracts to Develop a HIV Preventative and a HIV Therapeutic Vaccine